Partners & Collaborations

INDUSTRY

Janssen Pharmaceuticals - The development of ADX71149 is part of a worldwide research collaboration and license agreement between Addex and Janssen Pharmaceuticals, Inc. to discover, develop and commercialize a novel mGluR2 PAM medication for the treatment of anxiety, schizophrenia and other undisclosed indications. Under the terms of the agreement, Addex is eligible for up to a total of €112 million in milestone payments based on potential development and regulatory achievements. In addition, Addex is eligible for low double-digit royalties on sales of any mGluR2 PAM medication developed under the agreement.

-

ACADEMIA

We collaborate with leading researchers to advance the scientific field of neuroscience from top universities. These include:

Professor Ron Stoop - Addex is collaborating with Professor Ron Stoop of the Université de Lausanne to understand the function of mGluR4 and mGluR7 by assessing Addex compounds ADX88178 (mGluR4 PAM) and ADX71743 (mGluR7 NAM) using electrophysiological techniques.

Dr Bernard Schneider - Dr Bernard Schneider – EPFL – Addex is collaborating with Dr Bernard Schneider of the EPFL to evaluate the disease modifying potential of mGluR4 PAMs in a model of Parkinson’s disease that overexpresses the genetically and neuropathologically linked presynaptic neuronal protein alpha-synuclein.

Professor Dirk Dressler - Hanover Medical School – Addex is collaborating with Professor Dirk Dressler of the Hanover Medical School to initiate clinical testing of the therapeutic effect of dipraglurant in patients with dystonia.

Professor Antonio Pisani - University of Rome Tor Vergata and Fondazione Santa Lucia – Addex is collaborating with Professor Antonio Pisani of the University of Rome Tor Vergata to explore the use of dipraglurant to treat rare genetic forms of dystonia. The collaboration will evaluate the effect of chronic treatment with dipraglurant (ADX48621), on rescuing the synaptic plasticity deficits, in several models of genetic forms of dystonia, including the DYT1 knock-in mouse model.

Professor Andrzej Pilc - Polish Academy of Sciences – Addex is collaborating with Professor Andrzej Pilc of the Polish Academy of Sciences to explore the efficacy of dipraglurant in preclinical models of anxiety and depression. The collaboration has demonstrated anxiolytic and antidepressant efficacy of dipraglurant in multiple preclinical models relevant for non-motor symptoms of Parkinson’s disease.

Professor Jyoti Sengupta - Medical College of Wisconsin – Addex is collaborating with Professor Jyoti Sengupta of the Medical College of Wisconsin to evaluate the pharmacology of ADX71441 a GABAB receptor positive allosteric modulator (PAM), in preclinical models of visceral pain during urinary bladder inflammation.

Professor John Cryan - University College Cork- Addex is collaborating with Professor John Cryan of the University College Cork in Ireland to evaluate the pharmacology of ADX71743. The collaboration has demonstrated the efficacy of ADX71743, a negative allosteric modulator (NAM) of the metabotropic glutamate receptor subtype 7 (mGlu7 receptor), in a rat model of stress-sensitive visceral hypersensitivity, representing the first pharmacological study to implicate mGlu7 receptor in visceral pain processes.

Professor Michael Sereda - Max Planck Institute – Addex is collaborating with Professor Michael Sereda of the Max Planck Institute to evaluate the efficacy of Addex drug candidate ADX71441, a GABAB receptor positive allosteric modulator (PAM), in a preclinical model of CMT1A, a rare peripheral neuropathy. The collaboration has demonstrated that ADX71441 dose dependently reduced PMP-22 expression comparable to baclofen (a selective GABAB receptor agonist), in effect reducing the amount of hypo-myelinated axons and increased compound muscle action potentials in peripheral nerves when compared to vehicle treated CMT rats.

-

GOVERNMENTAL ORGANISATIONS

National Institute on Alcohol Abuse and Alcoholism – The National Institute on Alcohol Abuse and Alcoholism (NIAAA), a component of the National Institutes of Health (NIH) is collaborating with Addex to evaluate the pharmacology of ADX71441, a GABAB receptor positive allosteric modulator (PAM), in preclinical models of alcohol use disorder. The collaboration will evaluate Addex drug candidate, ADX71441, in a battery of preclinical models to study its potential as a treatment for alcohol use disorder.

National Institute on Drug Abuse – The National Institute on Drug Abuse (NIDA), a component of the National Institutes of Health (NIH) is collaborating with Addex to evaluate the pharmacology of ADX71441, a GABAB receptor positive allosteric modulator (PAM), and ADX88178, an mGlu4 PAM in preclinical models of drug abuse and addiction. The collaboration will evaluate Addex drug candidates, ADX71441 and ADX88178 in a battery of preclinical models to study their potential as treatments for nicotine and cocaine addiction.

National Institute on Alcohol Abuse and Alcoholism

 

NON-GOVERNMENTAL ORGANISATIONS

The Michael J Fox Foundation for Parkinson’s Research - The Michael J. Fox Foundation for Parkinson's Research awarded a $ 1.8 Million grant to Addex to help fund continued human clinical testing of dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia (PD-LID). One-third of people with PD develop dyskinesia within four to six years of beginning levodopa treatment; this increases to approximately 90 percent after nine or more years. Patients with Parkinson's disease (PD) can live 10-20 years after diagnosis; however, PD-LID is a leading cause of disability in this growing patient population.

Dystonia Medical Research Foundation - The Dystonia Medical Research Foundation (DMRF) is collaborating with Addex to explore the use of dipraglurant to treat dystonia, the third most common movement disorder following essential tremor and Parkinson’s disease. Dipraglurant, a novel small molecule inhibitor of the metabotropic glutamate receptor 5, has shown promise in the treatment of levodopa-induced dyskinesia and dystonia in Parkinson’s disease. Dipraglurant has also been shown to normalize the effects of the TOR1A/DYT1 dystonia mutation in the brains of mice. The objective of the collaboration is to design a detailed development plan and regulatory path as well as identifying key option leaders and patients for a Phase 2 clinical trial.

Charcot Marie Tooth Association - The Charcot-Marie-Tooth Association (CMTA) is collaborating with Addex to evaluate the pharmacology of ADX71441, a GABA-B receptor positive allosteric modulator (PAM) in a battery of preclinical models of Charcot-Marie-Tooth 1A disorder (CMT1A), a rare hereditary motor and sensory demyelinating peripheral neuropathy.

Non-Governmental organisations